X

Supply constraint of Creon® 10000 Creon® 25000 (Pancreatin)
4th July 2024

As the marketing authorisation holder and distributor of Creon® in the UK, we were notified by our third-party manufacturing partner, Abbott, of a supply constraint of Creon® (pancreatin) in the UK.

This constrained supply is due to high global demand and reaching maximum manufacturing supply output.

Creon® is a biologic product with a natural variation of its raw material and is made using a complex manufacturing process. The complexity of the process means that the ability to increase manufacturing capacity in the short-term is limited.

There is a long-term strategic initiative between Viatris and Abbott to increase the supply output of Creon® at the manufacturing facility. This work has already begun with expected completion in 2026.

During this supply constraint, we hope to be able to supply approximately 90-95% of the average monthly demand for Creon® lipase units into the market each month, until this supply constraint is resolved.

If you require additional information or have any questions, please contact customer services on 01707 853100 or via email; productenquiries@viatris.co.uk. For medical enquiries please contact our medical information team on 01707 853 000 or via email; info.uk@viatris.co.uk.

UK-CRE-2024-00006 July 2024

Keywords..

How Creon® works

How does Creon® help me absorb food?

When you have Pancreatic Exocrine Insufficiency (PEI), either the pancreas does not produce enough enzymes to break down food, the enzymes are not able to reach the food or the enzymes are not activated/they become deactivated.


Creon® is a type of pancreatic enzyme replacement therapy (PERT).
Creon® can provide the extra enzymes the body needs.

Creon® is available in different strengths; 25,000, 10,000 and Creon® Micro (5,000). The number refers to how much lipase it contains. You may find that you move to a different strength of Creon® depending upon how severe your PEI is.

You are leaving the Creon® patient website

You are now connecting to a website that is neither owned nor under the control of Viatris. Viatris is not responsible for the content of this site or any further links.
Please press OK to proceed or BACK to return to the Creon® patient website.
BACK
OK

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?

OK
NO
If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme.
It is easiest and quickest to report side effects and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at pv.uk@viatris.com.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781).

Creon® is indicated for the treatment of pancreatic exocrine insufficiency.

We recommend that you read the full patient information leaflets carefully before using Creon® 

UK-CRE-2024-00025 November 2024

This website is owned and managed by Viatris. For more information visit viatris.co.uk

Copyright © 2024 Viatris Inc. All rights reserved.